Submit Science - International Stroke Conference 2026

ISC27 Abstracts:

Submission opens: Wednesday, May 27, 2026
Submission closes: Tuesday, August 18, 2026 at 11:59 p.m. CDT/UTC-5

Deadline to add Authors or revise Submission:
August 18, 2026, 11:59 pm CDT/UTC-5.

Request for Abstract Withdrawal (in writing):
November 30, 2026

Submission Fees:

• AHA Professional Members: $45
• Nonmembers: $95

Rules for Submission of Abstract(s)

Author Name(s)

1. If an author's name appears on more than one abstract, it must be identical on each abstract.
2. The submitting author is designated as the presenting author. You may change who is presenting the abstract in the “Authors” step of the submission site. You may rearrange the order of the authors; however, the senior author must always be listed last. The presenter must be an author of the abstract.
3. There is no limit to the number of abstracts an investigator may submit. If selected, the presenter must be one of the co-authors listed. If multiple submissions are accepted, the presenting author must resolve schedule conflicts by arranging for a co-author to present.
4. Additions or deletions of author names will not be permitted after August 18, 2026, 11:59 p.m. CDT/UTC-5.

Abstract Data

1. Abstract data may not be presented at any national or international meeting held prior to the date and time of presentation at ISC 2027 or time of American Heart Association news event.
2. The International Stroke Conference 2027 is a forum for the presentation of novel research findings. Thus, the work covered by the abstract must not have been published (manuscript or abstract) prior to the time of abstract submission. Abstracts associated with a manuscript published between the time of submission and time of presentation may still be presented at ISC 2027 but will not be included in the Stroke journal abstract publication. Authors must contact American Heart Association staff to be removed from the abstract publication prior to the event. Please notify American Heart Association staff by sending an e-mail to [email protected].
3. Authors should not "split" data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.
4. Abstracts containing identical or nearly identical data submitted from the same institution and/or individuals will be disqualified.
5. Because of the large number of submitted abstracts, resubmission of an abstract to make revisions is not permitted after August 18, 2026, 11:59 p.m. CDT/UTC-5
6. To ensure that the abstract receives proper scientific consideration, please make sure that the abstract is submitted to the appropriate category. A list of the abstract categories and their definitions is available on the submission site.
7. Proofread abstracts carefully to avoid errors before submission. No proof pages will be sent to authors. Revisions to abstracts will not be permitted after the August 18, 2026, 11:59 p.m. CDT/UTC-5 submission deadline.

Use of Automated Assistive Writing Technologies and Tools

1. The use of automated assistive writing technologies and tools (commonly referred to as artificial intelligence or machine learning tools) is permitted provided their use is documented, and authors assume responsibility for the content. The authors are responsible for the accuracy, validity and originality of computer-generated content. Automated assistive writing technologies do not qualify for authorship as they are unable to provide approval or consent for submission.
2. If the use of these technologies has involved the research design, the tools should be documented in the abstract.
3. Not Acceptable use:
   • AI-generated abstract with minimal or no human revision
   • AI-generated scientific ideas, claims, data, or conclusions
4. For additional information, see the World Association of Medical Editor recommendations.
5. For your abstract submission, you will need to indicate the use of these tools.

Abstract Title

1. An abstract must have a short, specific title (containing no abbreviations) that indicates the nature of the investigation.

Abstract Text

1. Describe briefly the objectives of the study unless they are contained in the title. Include a brief statement of methods. State findings in detail sufficient to support conclusions. Abstracts should not describe research in which the chemical identity or source of the reagent is proprietary or cannot be revealed.
2. Abstracts may have the following identifiable sections, but they are not mandatory: Introduction, Hypothesis, Methods, Results and Conclusions. You may include a hypothesis, but only if it is appropriate to do so.
3. The abstract must contain a brief section on Methods/Methodology.
4. Use generic drug names.
5. Do not begin sentences with numerals.
6. Standard abbreviations may be used without definition. Non-standard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
7. Do not include author or institution names, references, credits or grant support in the abstract.
8. Do not include the names or personal information of any patient participating in the study or trial.
9. Abstracts are limited to 2,500 characters (about 500 - 600 words). This includes spaces and punctuation. It does not include graphics. Only 3 graphics max per abstract are allowed.
10. Tables must be submitted as graphics. Do not submit a table in Word as it will not format correctly in the online Stroke journal.
11. Due to new accessibility guidelines, you must submit a brief description of any and all graphics included in your abstract submission in the appropriate step on the submission site.

Graphics Guidelines

1. All graphics (figures) and text-based graphics (tables) should be provided as 72 - 300 dpi; pre-sized .BMP, .GIF, .JPG, or .PNG images only, with a maximum width of 440 pixels (no limit on length). Black-and-white digital images should be in grayscale mode. Color images should be saved in RGB color mode.
2. Only 3 graphics max per abstract are allowed.
3. All graphics will require a brief description of the image.
4. Please Note: If an abstract is accepted for publication, any images submitted with the abstract are placed after the abstract text that will appear in the online only Stroke journal, an American Heart Association journal.

Abstract Revisions

1. After the August 18, 2026, 11:59 p.m. CDT/UTC-5 deadline, abstracts may not be revised in any way or resubmitted.
2. Additions or deletions of author names will not be permitted after August 18, 2026, 11:59 p.m. CDT/UTC-5.
3. Proofread abstracts carefully to avoid errors before submission.

Abstract Copyright Transfer Agreement

Abstract Copyright Transfer Agreement will be electronically signed during submission.

• Your selection of “Yes” will grant permission to publish.
• Your selection of “No” will prohibit publication of the abstract in all formats including the online Stroke journal, ePoster site, the mobile meeting guide app, and the online program planner.

Acceptance

1. Abstracts selected will be published online in February 2027 on the Stroke Journal web site.
2. All communications regarding your abstract will be sent from [email protected]. Please make sure to add this e-mail address to your e-mail contacts to ensure important program participant related information gets through your spam filters, etc.
3. If the abstract is submitted to more than one meeting, investigators must include new and scientifically meaningful information/results at time of submission to the American Heart Association.
4. Abstracts accepted for presentation at ISC 2027 cannot be presented at another national or international meeting held prior to February 12, 2027.
5. The work covered by the abstract must not be published prior to the time of abstract submission. Abstracts associated with a manuscript published between the time of submission and time of presentation may still be presented at ISC 2027 but will not be included in the Stroke journal abstract publication. Authors must contact American Heart Association staff to be removed from the abstract publication prior to the event. Please notify staff by sending an e-mail to [email protected].
6. Abstract grading is blinded. Abstracts are selected on the basis of scientific merit and are allocated to oral or poster presentations.
7. Guidelines for presentations will be provided to authors of accepted abstracts.
8. Abstract acceptance/non-acceptance status will be e-mailed to the submitting author in late October to the e-mail address provided during the submission process.

Abstract Journal Publication

Accepted abstracts having selected “Yes” to the Abstract Copyright Transfer Agreement will be published online in the Stroke journal.

Embargo Policy

Non-late breaking abstracts and presentations are embargoed for release at 5:00 a.m. EST, Thursday, February 4, 2027, and are therefore prohibited from release until date and time of American Heart Association designated embargo time. You will be contacted by American Heart Association Communications if you are selected to participate in an news event.

Written embargoed information cannot be shared with anyone outside of the American Heart Association with the exception of a journal manuscript where one-on-one embargoed media interviews can be conducted as long as the reporter agrees to abide by the embargo policy. Failure to honor embargo policies will result in this abstract being withdrawn and future abstracts also being barred from presentation.

Abstracts associated with a manuscript published between the time of submission and time of presentation may still be presented at ISC 2027 but will not be included in the Stroke journal abstract publication. Authors must contact American Heart Association staff to be removed from the abstract publication prior to the event. Please notify staff by sending an e-mail to [email protected].

Complete American Heart Association Embargo Policy

Presentation

1. Request “oral or poster” or “poster only” preferred presentation on the Properties tab of the Submitter Site. The selection of one of these options will neither prejudice acceptance nor guarantee an oral or poster presentation because abstracts must be arranged to fit into a thematic group for presentation.
2. All presentations and question-and-answer sessions will be conducted in English. Presenters may request assistance from the moderator who will repeat or rephrase questions from the audience, or they may ask a colleague in the audience to help translate.
3. Submission of an abstract constitutes a commitment by the author(s) to present it if accepted. Failure to present, if not justified, will jeopardize future acceptance of abstracts.
4. The American Stroke Association, a division of the American Heart Association, reserves the right to all video or audio recordings of presentations at the International Stroke Conference 2025.
5. The presenter is responsible for all expenses associated with the submission and presentation of an abstract (e.g. registration, airfare, lodging, etc.).
6. All oral presentations must be in electronic format. Electronic presentations must be submitted via the Presentation Management system at least 12 hours in advance of the session start time. Instructions will be sent to the presenting author via e-mail in early January 2025.
7. If you are referencing work previously published by another author, please be sure to include a complete citation at the bottom of the appropriate slide.

Recording Policy

1. Unauthorized recording of Scientific Sessions, scientific conferences, and American Heart Association's International Stroke Conference and ISC Pre-Conference Symposia is prohibited, whether by video, still or digital photography, audio or any other recording or reproduction mechanism. This includes recording of presentations and supporting audiovisual materials and of poster presentations and supporting poster materials.
2. The American Heart Association and American Stroke Association reserve the rights to all recordings or reproductions of presentations at Association scientific conferences and meetings.

Abstract Withdrawal

1. Requests for withdrawal of an abstract must be received in writing by November 30, 2026.

The suggestions below are intended to provide guidance on abstract writing.

Title: To the extent the data permits, make the title dynamic and conclusive, rather than descriptive. For example, "Hypoxia Inhibits Kv1.5 Channels in Rat Pulmonary Artery Smooth Muscle Cells" is preferable to "Effects of Hypoxia on Kv1.5 Channels." Explicit titles denoting the findings should be used (not “Investigations of…", "Studies of…", etc.).

Structure: Abstracts may have the following identifiable sections, but they are not mandatory: Introduction, Hypothesis, Methods, Results and Conclusions.
You may include a hypothesis, but only if it is appropriate to do so.
The abstract must contain a brief section on Methods/Methodology.

Category: Be sure to select the correct abstract category. Category selection determines which review team grades the abstract. You MAY also select a "Secondary Category"; the additional category is optional. Do NOT select an additional, secondary category if it does not fit your submission. If you select the appropriate category, your abstract will be blindly graded by experts familiar with the science of the category.

Abbreviations: Abbreviations may be used after they are spelled out or defined. Use generic, not commercial, names for all therapeutic agents.

Proofread your work: Be sure to proofread your work carefully including the author block. If accepted, your abstract will be printed as submitted. No changes will be allowed to the abstract or the author block after the deadline of August 18, 2026, 11:59 pm CDT/UTC-5..

Common Mistakes

1. Failure to include a brief section on Methods/Methodology.
2. Failure to state a conclusion. We encourage a final sentence that says: "In conclusion …".
3. Failure to state sample size. The reviewers want to assess the quality of the data - they need a mean SEM and a sample size.
4. Excessive use of abbreviations. All but the most standard abbreviations should be defined and most abstracts should have less than 3 abbreviations.

Traps to Avoid

1. Typographical errors.
2. References cited in the abstract.
3. Not providing context or a statement of relevance that provides the rationale for your study.
4. Complex graphics. Simple line or bar graphs are most appropriate. Ensure the font size is adequately large on each axis to be visible. Check a printed version of the abstract before submitting. Tables must be submitted as graphics.
5. Leaving abstract writing until the 11th hour - this increases stress and leads to errors.
6. Duplicative work.

Remember: Make sure your abstract is clear, concise, and follows all rules. Show your abstract to a colleague prior to submission and modify accordingly. A fresh pair of eyes will help spot any errors and will ensure the final product is ready for submission.

State-of-the-Science Stroke Nursing Symposium:

Submission opens: Wednesday, May 27, 2026
Submission closes: Tuesday, August 18, 2026 at 11:59 p.m. CDT/UTC-5

Deadline to add authors or revise submission:
August 18, 2026, 11:59 pm CDT/UTC-5.

Deadline to request abstract withdrawal (in writing):
November 30, 2026

Submission Fees:

• American Heart Association Professional Members: $45
• Nonmembers: $95

You MUST select at least one category; this is mandatory. You MAY also select a “Secondary Category”; the additional category is optional. Do NOT select an additional, secondary category if it does not fit your submission.

Note: There may be some overlap of definitions/terms among categories. Please aim for topic specificity as much as possible.

Acute Ischemic Stroke Management
Focuses on emergency medical management, including neuroprotection, thrombolysis, adjunct therapies and advanced revascularization techniques.

Arteriosclerosis, Thrombosis, and Vascular Biology
Focuses on vascular processes and risk factors—such as atherosclerosis and thrombotic events—that contribute to stroke.

Brain Health and Cognitive Impairment
Covers basic, clinical, experimental, and population-based investigations into relationships between stroke, cerebrovascular disease, and cognitive outcomes. Explores neuroimaging correlates and predictors of cognitive impairment, with a particular (but not exclusive) focus on small vessel disease and vascular dementia.

Cerebrovascular Systems and Multidisciplinary Models of Care
Reviews integrated care models designed to optimize stroke treatment across various healthcare settings.

Epidemiology, Risk Factors, and Prevention
Examines population studies, disease patterns, established and emerging risk factors, and preventive strategies, emphasizing public health approaches.

Global Stroke Disparities and Equity
Examines worldwide social determinants of cerebrovascular health, strategies for improving access to evidence-based care in culturally relevant ways, and efforts toward achieving greater equity in stroke outcomes.

Health Services, Quality Improvement, and Patient-Centered Outcomes
Explores strategies to enhance healthcare delivery and research design and ensure treatments align with patient needs and experiences.

Hemorrhagic Stroke Treatment
Dedicated to the latest approaches for managing intracerebral and subarachnoid hemorrhages.

Imaging in Stroke
Explores advances in neuroimaging techniques for stroke diagnosis, management, and prognosis.

Molecular and Cellular Brain Science
Explores the cellular and molecular foundations of stroke, deepening our understanding of neurobiology and pathophysiology.

Neurocritical Care and Complex Brain Physiology
Addresses the intensive care of stroke patients, including advanced monitoring, interventions, and long-term outcomes.

Neuroimmunology and Inflammation in Stroke
Investigates how immune and inflammatory processes influence stroke onset, acute pathological evolution, and recovery, opening doors for new therapeutic targets.

Neurointervention
Focuses on endovascular and surgical neurointerventional strategies in stroke and neurovascular conditions.

Omics, Big Data, Precision Medicine, Bioengineering, and Artificial Intelligence
Highlights genomic, proteomic, and computational strategies shaping personalized stroke care. Showcases how technology and data-driven tools are transforming stroke diagnosis, treatment, and research, as well as how digital solutions and telehealth are reshaping both acute and long-term stroke care.

Pediatric Stroke
Dedicated to the unique pathophysiology, challenges, and treatment protocols for stroke in children.

Post-Stroke Care
Covers best practices for stroke units, secondary prevention, and long-term management strategies.

Practical Updates and Clinical Conundrums
Features case-based discussions and expert panels addressing real-world challenges in stroke management.

Psychosocial and Behavioral Aspects of Stroke
Examines mental health, behavioral challenges, and social support systems crucial for stroke recovery.

Regenerative Medicine and Novel Therapeutic Strategies
Explores emerging treatments such as stem cell therapy, human-machine interfaces/devices, and novel drug delivery methods aimed at repair, functional recovery, and regeneration.

Rehabilitation and Recovery
Highlights innovative rehabilitation methods and long-term support strategies for stroke survivors.

Translational Research, Therapeutic Development, and Biomarkers
Bridges basic science with clinical practice by highlighting innovative therapies and the discovery of new biomarkers.

Vascular Malformations, Aneurysms, Moyamoya, and Other Vascular Conditions
Addresses congenital and acquired vascular anomalies, their impact on stroke risk, approaches to care, and outcomes.

Author Name(s)

1. If an author's name appears on more than one abstract, it must be identical on each abstract.
2. The submitting author is designated as the presenting author. You may change who is presenting the abstract on the “Authors” step of the submission site. You may rearrange the order of the authors; however, the senior author must always be listed last. The presenter must be an author of the abstract.
3. There is no limit to the number of abstracts an investigator may submit. If selected, the presenter must be one of the co-authors listed. If multiple submissions are accepted, the presenting author must resolve schedule conflicts by arranging for a co-author to present.
4. Additions or deletions of author names will not be permitted after August 18, 2026, 11:59 pm CDT/UTC-5.

Abstract Requirements

1. Abstract data may not be presented and any national or international meeting held prior to the date and time of presentation at ISC or the Stroke Nursing Symposium 2027 or time of American Heart Association News event.
2. Abstracts must be an original idea, concept, or an improvement or revision of an old idea.
3. Abstracts must be submitted in the final format. NO changes to content can be made after August 18, 2026, 11:59 pm CDT/UTC-5. Abstracts may not represent a work in progress.
4. The same abstract may be submitted for both ISC and the Stroke Nursing Symposium 2027, but it can only be accepted for and presented at either ISC or the Nursing Symposium.
5. The work covered by the abstract must not have been published (manuscript or abstract) prior to the time of abstract submission. Abstracts associated with a manuscript published between the time of submission and time of presentation may still be presented at ISC or the Stroke Nursing Symposium 2027 but will not be included in the Stroke journal abstract publication. Authors must contact American Heart Association staff to be removed from the abstract publication prior to the event. Please notify staff by sending an e-mail to [email protected].

Abstract Data

1. Abstracts should address clinical quality initiatives, projects or policies from professionals that are pioneers in improving the quality of care and outcomes for persons with or at risk for stroke.
2. Abstracts may also address issues in development or maintaining a stroke program.
3. Abstracts with research findings should be submitted to the International Stroke Conference in the appropriate category.
4. Because of the large number of submitted abstracts, resubmission of an abstract to make revisions is not permitted after August 18, 2026, 11:59 pm CDT/UTC-5.
5. To ensure that the abstract receives proper scientific consideration, please make sure that the abstract is submitted to the appropriate category. A list of the abstract categories and their definitions is available on the submission site.
6. Proofread abstracts carefully to avoid errors before submission. No proof pages will be sent to authors. Revisions to abstracts will not be permitted after the August 18, 2026, 11:59 pm CDT/UTC-5 submission deadline.
7. The American Heart Association is committed to upholding the highest standards of scientific integrity in all abstracts submitted to its scientific meetings. By submitting an abstract, authors confirm that the work is original, accurately presented, and consistent with the American Heart Association’s standards for ethical and responsible scientific communication. All abstracts submitted to American Heart Association scientific meetings are subject to peer review and may undergo additional scientific integrity assessments, which may include expert evaluation and analytical tools to identify concerns related to originality, authorship, ethical conduct, or appropriate use of emerging technologies. Abstracts that do not meet the Association’s scientific or ethical standards may be subject to further review or disqualification.

Use of Automated Assistive Writing Technologies and Tools

1. The use of automated assistive writing technologies and tools (commonly referred to as artificial intelligence or machine learning tools) is permitted provided their use is documented, and authors assume responsibility for the content. The authors are responsible for the accuracy, validity and originality of computer-generated content. Automated assistive writing technologies do not qualify for authorship as they are unable to provide approval or consent for submission.
2. If the use of these technologies has involved the research design, the tools should be documented in the abstract.
3. Not Acceptable use:
   • AI-generated abstract with minimal or no human revision
   • AI-generated scientific ideas, claims, data, or conclusions
4. For additional information, see the World Association of Medical Editor recommendations.
5. For your abstract submission, you will need to indicate the use of these tools.

Abstract Title

1. An abstract must have a short, specific title (containing no abbreviations) that indicates the nature of the investigation.

Abstract Text

1. Do not begin sentences with numerals.
2. Use generic drug names.
3. Standard abbreviations may be used without definition. Non-standard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
4. Do not include author or institution names, references, credits or grant support.
5. Do not include the names or personal information of any patient participating in the study or trial.
6. Abstracts are limited to 2,500 characters (about 500–600 words). This includes spaces and punctuation. It does not include graphics. Only 3 graphics max per abstract are allowed.
7. Tables must be submitted as graphics. Do not submit a table in Word as it will not format correctly in the online Stroke journal.
8. Due to new accessibility guidelines, you must submit a brief description of any and all graphics included in your abstract submission in the appropriate step on the submission site:

Abstract acceptance/non-acceptance criteria

Nursing Symposium abstract grading will be based on the following: 

• Scientific Merit: The topic is pertinent to the development of knowledge related to stroke clinical practice and is relevant to the purpose of the State-of-the-Science Stroke Nursing Symposium.
• Practicality: The abstract enhances the foundation for clinical decision-making or stimulates thinking about practice applications when caring for the stroke patient.
• Organization: Overall, the abstract is readable and accurately presented and conclusion valid.
• Presentation: The presentation demonstrates an insightful application or/a creative and original solution to a clinical practice issue or problem in caring for the stroke patient.
• Technical quality: 
  The abstract must include complete information or outcomes and have scientific backing. (Mentioning that the results will be presented at the meeting is unsatisfactory.)

Research-Based Abstracts

• Background: Description of the problem.
• Purpose: Research questions or hypothesis.
• Methods: Study design, including a description of participants, procedures, measures, and appropriate statistical analyses.
• Results: Specific results in summary form.
• Conclusions: Major findings are presented with interpretation and implications for stroke management and nursing practice.

Clinical Practice/Program/QI Project Abstracts

• Background and Issues: A short summary of the issue(s), problem, or specific clinical challenges or controversy, with relevant background and contextual information.
• Purpose: Clear statement of goal of project is described.
• Methods: Description of the project or program, clinical intervention(s), analysis plan or criteria used to guide analysis.
• Results: Lessons Learned: A brief description of the findings or lessons learned as a result of the project.
• Conclusions: A brief description of recommended position or approach, or specific recommendations related to the original problem or questions identified.

Graphics Guidelines

1. All graphics (figures) and text-based graphics (tables) should be provided as 72–300 dpi; pre-sized .BMP, .GIF, .JPG, or .PNG images only, with a maximum width of 440 pixels (no limit on length). Black-and-white digital images should be in grayscale mode. Color images should be saved in RGB color mode.
2. Only 3 graphics max per abstract are allowed.
3. All graphics will require a brief description of the image.
4. Please Note: If an abstract is accepted for publication, any images submitted with the abstract are placed after the abstract text that will appear in the online only Stroke journal, an American Heart Association journal.

Abstract Revisions

1. After the August 18, 2026, 11:59 pm CDT/UTC-5 deadline, abstracts may not be revised in any way or resubmitted.
2. Additions or deletions of author names will not be permitted after August 18, 2026, 11:59 pm CDT/UTC-5.
3. Proofread abstracts carefully to avoid errors before submission.

Abstract Copyright Transfer Agreement

Abstract Copyright Transfer Agreement will be electronically signed during submission.

• Your selection of “Yes” will grant permission to publish.
• Your selection of “No” will prohibit publication of the abstract in all formats including the online Stroke journal, ePoster site, the mobile meeting guide app, and the online program planner.

Acceptance

1. Abstracts selected will be published online in February 2027 on the Stroke journal Web site.
2. All communications regarding your abstract will be sent from [email protected]. Please make sure to add this e-mail address to your e-mail contacts to ensure important program participant related information gets through your spam filters, etc.
3. If the abstract is submitted to more than one meeting, investigators must include new and scientifically meaningful information/results at time of submission to the American Heart Association.
4. Abstracts accepted for presentation at ISC or the Stroke Nursing Symposium 2027 cannot be presented at another national or international meeting held prior to February 12, 2027.
5. The work covered by the abstract must not be published prior to the time of abstract submission. Abstracts associated with a manuscript published between the time of submission and time of presentation may still be presented at ISC or the Stroke Nursing Symposium 2027 but will not be included in the Stroke journal abstract publication. Authors must contact AHA staff to be removed from the abstract publication prior to the event. Please notify American Heart Association staff by sending an e-mail to [email protected].
6. Abstract grading is blinded. Abstracts are selected on the basis of scientific merit and are allocated to oral or poster presentations.
7. Guidelines for presentations will be provided to authors of accepted abstracts.
8. Abstract acceptance/non-acceptance status will be e-mailed to the submitting author in late October to the e-mail address provided during the submission process.

Abstract Journal Publication

Accepted abstracts having selected “Yes” to the Abstract Copyright Transfer Agreement will be published online in the Stroke journal.

Embargo Policy

Non-late breaking abstracts and presentations are embargoed for release at 5 a.m. EST, Thursday, February 4, 2027, and are therefore prohibited from release until date and time of AHA designated embargo time. You will be contacted by AHA communications if you are selected to participate in an AHA news event.

Written embargoed information cannot be shared with anyone outside of the AHA with the exception of a journal manuscript where one-on-one embargoed media interviews can be conducted as long as the reporter agrees to abide by the embargo policy. Failure to honor embargo policies will result in this abstract being withdrawn and future abstracts also being barred from presentation.

Abstracts associated with a manuscript published between the time of submission and time of presentation may still be presented at ISC or the Stroke Nursing Symposium 2027 but will not be included in the Stroke journal abstract publication. Authors must contact American Heart Association staff to be removed from the abstract publication prior to the event. Please notify AHA staff by sending an e-mail to [email protected].

See the complete American Heart Association Embargo Policy.

Presentation

1. Request “Any Format” or “Poster Board only” preferred presentation on the Properties tab of the Submitter Site. The selection of one of these options will neither prejudice acceptance nor guarantee an oral or poster presentation because abstracts will be assigned based on scientific merit and must be arranged to fit into a thematic group for presentation.
2. All Nursing Symposium abstracts accepted for poster presentation will be presented during the International Stroke Conference as the Stroke Nursing Symposium does not include poster sessions.
3. All presentations and question-and-answer sessions will be conducted in English. Presenters may request assistance from the moderator who will repeat or rephrase questions from the audience or may ask a colleague in the audience to help translate.
4. Submission of an abstract constitutes a commitment by the author(s) to present it if accepted. Failure to present, if not justified, will jeopardize future acceptance of abstracts.
5. The American Stroke Association, a division of the American Heart Association, reserves the right to all video or audio recordings of presentations at the State-of-the-Science Stroke Nursing Symposium 2027, Pre-Conference Symposia 2027, and the International Stroke Conference 2027.
6. The presenter is responsible for all expenses associated with the submission and presentation of an abstract (e.g. registration, airfare, lodging, etc.).
7. All oral presentations must be in electronic format. Electronic presentations must be submitted at least 12 hours in advance of the session start time. Instructions will be sent to the presenting author via e-mail in early January 2027.
8. If you are referencing work previously published by another author, please be sure to include a complete citation at the bottom of the appropriate slide.

Recording Policy:

1. Unauthorized recording of the American Heart Assocation's Scientific Sessions, scientific conferences, and the Association's International Stroke Conference, Stroke Nursing Symposium and ISC Pre-Conference Symposia is prohibited, whether by video, still or digital photography, audio or any other recording or reproduction mechanism. This includes recording of presentations and supporting audiovisual materials and of poster presentations and supporting poster materials.
2. The American Heart Association and American Stroke Association reserve the rights to all recordings or reproductions of presentations at American Heart Association/American Stroke Association scientific conferences and meetings.

Abstract Withdrawal

1. Requests for withdrawal of an abstract must be received in writing by November 30, 2026.

Many abstracts are submitted to the State-of-the-Science Stroke Nursing Symposium each year. The following suggestions may improve the chances of your work being selected for presentation at the annual symposium.

Suggestions for writing a better abstract:

Title: To the extent the data permits, make the title dynamic and conclusive, rather than descriptive. For example, "Hypoxia inhibits Kv1.5 channels in rat carotid artery smooth muscle cells" is preferable to "Effects of hypoxia on Kv1.5 channels." Explicit titles denoting the findings should be used (not "Investigations of...," "Studies of...," etc.)

Structure: A good Nursing Symposium abstract should have these identifiable sections: Background, Purposes, Methods, Results, Conclusions.

Category: You can increase the odds of success by making sure you have selected the appropriate category. The category determines which team grades the abstract. If you select the appropriate category, you are more likely to be graded by peers with similar interests and who are familiar with your work. A complete list of the abstract categories and their definitions is available on the submission site.

Abbreviations: Abbreviations may be used after they are spelled out or defined. Use generic, not commercial, names for all therapeutic agents.

Proofread your work: Be sure to proofread your work carefully including the author block. If accepted, your abstract will be printed as submitted. No changes will be allowed to the abstract or the author block after the deadline of August 18, 2026, 11:59 p.m. CDT/UTC-5.

Common mistakes:

1. Failure to state the purpose. It is advisable to formally state: "The purpose of this trial/study/program is…"
2. Failure to state a conclusion. Use a final sentence that reads: "In conclusion,…"
3. Failure to state sample size. The reviewer wants to assess the quality of the data - they need a mean SEM and a sample size.
4. Excessive use of abbreviations. All but the most standard abbreviations should be defined and most abstracts should have < 3 abbreviations.

Traps to avoid:

1. Typographical errors.
2. References cited in the abstract.
3. Not providing content/statement of relevance that states the rationale for your study.
4. Using complex graphics. Simple line or bar graphs work best. Make sure the font is adequate on each axis to be seen. Check a printed version of the abstract before submission. Tables must be submitted as graphics.
5. Leaving abstract writing until the 11th hour - this increases stress and leads to errors.
6. Duplicated work.

How to avoid rejection

Make sure your abstract is clear, concise and follows all rules. Show your abstract to a colleague prior to submission and modify accordingly.

Nursing Symposium Abstract Requirements

1. Abstracts must be an original idea, concept, an improvement or revision of an old idea.
2. Abstracts must be submitted in the final format. NO changes to content will be made after receipt of submission. Abstracts may not represent a work in progress.
3. Abstracts that have been presented or will be presented at any national or international meeting prior to February 12, 2027 or have been submitted to more than one category of the Nursing Symposium will not be considered.
4. The same abstract may be submitted for both ISC and the Stroke Nursing Symposium, but it can only be accepted for and presented at either ISC or the Nursing Symposium.

Abstract Grading Criteria

Nursing Symposium abstract grading will be based on the following:

Abstract acceptance/non-acceptance criteria

• Scientific Merit: The topic is pertinent to the development of knowledge related to stroke clinical practice and is relevant to the purpose of the State-of-the-Science Stroke Nursing Symposium.
• Practicality: The abstract enhances the foundation for clinical decision-making or stimulates thinking about practice applications when caring for the stroke patient.
• Organization: Overall, the abstract is readable and accurately presented and conclusion valid.
• Presentation: The presentation demonstrates an insightful application or/a creative and original solution to a clinical practice issue or problem in caring for the stroke patient.
• Technical quality: The abstract must include complete information or outcomes and have scientific backing. (Mentioning that the results will be presented at the meeting is unsatisfactory.)

Research-Based Abstracts:

• Background: Description of the problem.
• Purpose: Research questions or hypothesis.
• Methods: Study design, including a description of participants, procedures, measures, and appropriate statistical analyses.
• Results: Specific results in summary form.
• Conclusions: Major findings are presented with interpretation and implications for stroke management and nursing practice.

Clinical Practice/Program/QI Project Abstracts

• Background and Issues: A short summary of the issue(s), problem, or specific clinical challenges or controversy, with relevant background and contextual information.
• Purpose: Clear statement of goal of project is described.
• Methods: Description of the project or program, clinical intervention(s), analysis plan or criteria used to guide analysis.
• Results: Lessons Learned: A brief description of the findings or lessons learned as a result of the project.
• Conclusions: A brief description of recommended position or approach, or specific recommendations related to the original problem or questions identified.

HEADS-UP Abstract Submission

Submission opens: Wednesday, May 27, 2026
Submission closes: Tuesday, August 18, 2026 at 11:59 p.m. CDT/UTC-5

Deadline to add Authors or revise Submission:
August 18, 2026, 11:59 pm CDT/UTC-5.

Request for Abstract Withdrawal (in writing):
November 30, 2026

Submission Fees:

• American Heart Association Professional Members: $45
• Nonmembers: $95

Author Name(s)

1. If an author's name appears on more than one abstract, it must be identical on each abstract.
2. The submitting author is designated as the presenting author. You may change who is presenting the abstract in the "Authors" step of the submission site. You may rearrange the order of the authors; however, the senior author must always be listed last. The presenter must be an author of the abstract.
3. There is no limit to the number of abstracts an investigator may submit. If selected, the presenter must be one of the co-authors listed. If multiple submissions are accepted, the presenting author must resolve schedule conflicts by arranging for a co-author to present.
4. Additions or deletions of author names will not be permitted after August 18, 2026 at 11:59 p.m. CDT/UTC-5.

Abstract Data

1. The International Stroke Conference 2027 and HEADS-UP 2027 are a forum for the presentation of novel research findings. Thus, the work covered by the abstract must not have been published (manuscript or abstract) prior to the time of abstract submission. Abstracts associated with a manuscript published between the time of submission and time of presentation may still be presented at ISC or HEADS-UP 2027 but will not be included in the Stroke journal abstract publication. Authors must contact AHA staff to be removed from the abstract publication prior to the event. Please notify AHA staff by sending an e-mail to [email protected].
2. Abstract data may not be presented at any national or international meeting held prior to the date and time of presentation or time of AHA news event.
3. Authors should not "split" data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.
4. Abstracts containing identical or nearly identical data submitted from the same institution and/or individuals will be disqualified.
5. Because of the large number of submitted abstracts, resubmission of an abstract to make revisions is not permitted after August 18, 2026, 11:59 pm CDT/UTC-5.
6. To ensure that the abstract receives proper scientific consideration, please make sure that the abstract is submitted to the appropriate category. A list of the abstract categories and their definitions is available on the submission site. You may also select an additional, secondary category, but it is not mandatory.
7. Proofread abstracts carefully to avoid errors before submission. No proof pages will be sent to authors. Revisions to abstracts will not be permitted after the August 18, 2026, 11:59 pm CDT/UTC-5 submission deadline.
8. The American Heart Association is committed to upholding the highest standards of scientific integrity in all abstracts submitted to its scientific meetings. By submitting an abstract, authors confirm that the work is original, accurately presented, and consistent with the American Heart Association’s standards for ethical and responsible scientific communication. All abstracts submitted to American Heart Association scientific meetings are subject to peer review and may undergo additional scientific integrity assessments, which may include expert evaluation and analytical tools to identify concerns related to originality, authorship, ethical conduct, or appropriate use of emerging technologies. Abstracts that do not meet American Heart Association;s scientific or ethical standards may be subject to further review or disqualification.

Use of Automated Assistive Writing Technologies and Tools

1. The use of automated assistive writing technologies and tools (commonly referred to as artificial intelligence or machine learning tools) is permitted provided their use is documented, and authors assume responsibility for the content. The authors are responsible for the accuracy, validity and originality of computer-generated content. Automated assistive writing technologies do not qualify for authorship as they are unable to provide approval or consent for submission.
2. If the use of these technologies has involved the research design, the tools should be documented in the abstract.
3. Not Acceptable use:
   • AI-generated abstract with minimal or no human revision
   • AI-generated scientific ideas, claims, data, or conclusions
4. For additional information, see the World Association of Medical Editor recommendations.
5. For your abstract submission, you will need to indicate the use of these tools.

Abstract Title

1. An abstract must have a short, specific title (containing no abbreviations) that indicates the nature of the investigation.

Abstract Text

1. Describe briefly the objectives of the study unless they are contained in the title. Include a brief statement of methods. State findings in detail sufficient to support conclusions. Abstracts should not describe research in which the chemical identity or source of the reagent is proprietary or cannot be revealed.
2. Abstracts may have the following identifiable sections, but they are not mandatory: Introduction, Hypothesis, Methods, Results and Conclusions. You may include a hypothesis, but only if it is appropriate to do so.
3. The abstract must contain a brief section on Methods/Methodology.
4. Use generic drug names.
5. Do not begin sentences with numerals.
6. Standard abbreviations may be used without definition. Non-standard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
7. Do not include author or institution names, references, credits or grant support in the abstract.
8. Do not include the names or personal information of any patient participating in the study or trial.
9. Abstracts are limited to 2,500 characters (about 500 - 600 words). This includes spaces and punctuation. It does not include graphics. Only 3 graphics max per abstract are allowed.
10. Tables must be submitted as graphics. Do not submit a table in Word as it will not format correctly in the online Stroke journal.
11. Due to new accessibility guidelines, you must submit a brief description of any and all graphics included in your abstract submission in the appropriate step on the submission site.

Graphics Guidelines

1. All graphics (figures) and text-based graphics (tables) should be provided as 72 - 300 dpi; pre-sized .BMP, .GIF, .JPG, or .PNG images only, with a maximum width of 440 pixels (no limit on length). Black-and-white digital images should be in grayscale mode. Color images should be saved in RGB color mode.
2. Only 3 graphics max per abstract are allowed.
3. All graphics will require a brief description of the image.
4. Please Note: If an abstract is accepted for publication, any images submitted with the abstract are placed after the abstract text that will appear in the online only Stroke journal, an American Heart Association journal.

Abstract Revisions

1. After the August 18, 2026, 11:59 pm CDT/UTC-5 deadline, abstracts may not be revised in any way or resubmitted.
2. Additions or deletions of author names will not be permitted after August 18, 2026, 11:59 pm CDT/UTC-5.
3. Proofread abstracts carefully to avoid errors before submission.

Abstract Copyright Transfer Agreement

Abstract Copyright Transfer Agreement will be electronically signed during submission.

• Your selection of "Yes" will grant permission to publish.
• Your selection of “No” will prohibit publication of the abstract in all formats including the online Stroke journal, ePoster site, the mobile meeting guide app, and the online program planner.

Acceptance

1. Abstracts selected will be published online in February 2027 on the Stroke journal Web site.
2. All communications regarding your abstract will be sent from [email protected]. Please make sure to add this e-mail address to your e-mail contacts to ensure important program participant related information gets through your spam filters, etc.
3. If the abstract is submitted to more than one meeting, investigators must include new and scientifically meaningful information/results at time of submission to the American Heart Association.
4. Abstracts accepted for presentation at ISC or HEADS-UP 2027 cannot be presented at another national or international meeting held prior to February 12, 2027.
5. The work covered by the abstract must not be published prior to the time of abstract submission. Abstracts associated with a manuscript published between the time of submission and time of presentation may still be presented at ISC or HEADS-UP 2027 but will not be included in the Stroke journal abstract publication. Authors must contact AHA staff to be removed from the abstract publication prior to the event. Please notify AHA staff by sending an e-mail to [email protected].
6. Abstract grading is blinded. Abstracts are selected on the basis of scientific merit and are allocated to oral or poster presentations.
7. Guidelines for presentations will be provided to presenting authors of accepted abstracts.
8. Abstract acceptance/non-acceptance status will be e-mailed to the presenting author in late October to the e-mail address provided during the submission process.

Abstract Journal Publication

Accepted abstracts having selected “Yes” to the Abstract Copyright Transfer Agreement will be published online in the Stroke journal.

Embargo Policy

Non-late breaking abstracts and presentations are embargoed for release at 5:00 a.m. EST, Thursday, February 4, 2027, and are therefore prohibited from release until date and time of AHA designated embargo time. You will be contacted by American Heart Assocation Communications if you are selected to participate in an Association news event.

Written embargoed information cannot be shared with anyone outside of the American Heart Assocation with the exception of a journal manuscript where one-on-one embargoed media interviews can be conducted as long as the reporter agrees to abide by the embargo policy. Failure to honor embargo policies will result in this abstract being withdrawn and future abstracts also being barred from presentation.

Abstracts associated with a manuscript published between the time of submission and time of presentation may still be presented at ISC 2027 but will not be included in the Stroke journal abstract publication. Authors must contact American Heart Assocation staff to be removed from the abstract publication prior to the event. Please notify staff by sending an e-mail to [email protected].

The suggestions below are intended to provide guidance on abstract writing.

Title: To the extent the data permits, make the title dynamic and conclusive, rather than descriptive. For example, “Hypoxia Inhibits Kv1.5 Channels in Rat Pulmonary Artery Smooth Muscle Cells” is preferable to “Effects of Hypoxia on Kv1.5 Channels.” Explicit titles denoting the findings should be used (not “Investigations of…”, “Studies of…”, etc.).

Structure: Abstracts may have the following identifiable sections, but they are not mandatory: Introduction, Hypothesis, Methods, Results and Conclusions. You may include a hypothesis, but only if it is appropriate to do so. The abstract must contain a brief section on Methods/Methodology.

Category: Be sure to select the correct abstract category. Category selection determines which review team grades the abstract. You may also select an optional Secondary Category. Do not select a secondary category if it does not fit your submission. If you select the appropriate category, your abstract will be blindly graded by experts familiar with the science of the category.

Abbreviations: Abbreviations may be used after they are spelled out or defined. Use generic, not commercial, names for all therapeutic agents.

Proofread your work: Be sure to proofread your work carefully including the author block. If accepted, your abstract will be printed as submitted. No changes will be allowed to the abstract or the author block after the deadline of August 19, 2025, 11:59 pm EDT.

Common Mistakes

1. Failure to include a brief section on Methods/Methodology.
2. Failure to state a conclusion. We encourage a final sentence that says: “In conclusion …”.
3. Failure to state sample size. The reviewers want to assess the quality of the data - they need a mean SEM and a sample size.
4. Excessive use of abbreviations. All but the most standard abbreviations should be defined and most abstracts should have less than 3 abbreviations.

Traps to Avoid

1. Typographical errors.
2. References cited in the abstract.
3. Not providing context or a statement of relevance that provides the rationale for your study.
4. Complex graphics. Simple line or bar graphs are most appropriate. Ensure the font size is adequately large on each axis to be visible. Check a printed version of the abstract before submitting. Tables must be submitted as graphics.
5. Leaving abstract writing until the 11th hour - this increases stress and leads to errors.
6. Duplicative work.

Remember: Make sure your abstract is clear, concise, and follows all rules. Show your abstract to a colleague prior to submission and modify accordingly. A fresh pair of eyes will help spot any errors and will ensure the final product is ready for submission.